Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

NCT00115219 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen